Drugs / B010-A
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 0 | NCT05070156 | Oct 2021 → Aug 2024 | hepatocellular carcinoma | Tongji University | Unknown | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | B010-A | “This is an Open-label, Single Arm study to observe the safety and tolerability of B010-A in the treatment of advanced hepatocellular carcinoma.” NCT05070156 ↗ |
| Modality | Cell therapy | “Targeting Glypican-3 (GPC3) Chimeric Antigen Receptor Modified T Cells (CAR-T)” NCT05070156 ↗ |
| Target | GPC3 | “Targeting Glypican-3 (GPC3) Chimeric Antigen Receptor Modified T Cells (CAR-T)” NCT05070156 ↗ |